

2024年 3月 21日

各位

「Newsweek International」掲載のお知らせ

当社の子会社であるあすか製薬株式会社（東京都港区）の代表取締役社長 山口惣大が、通信社 The Worldfolio PTE. LTD.の取材を受け、米国週刊誌「Newsweek International」に会社の紹介記事が掲載されましたのでお知らせいたします。

※記事内容は添付資料をご覧ください

※関連記事：「Newsweek International」掲載のお知らせ (2023 年 9 月 14 日公表)

<https://www.aska-pharma-hd.co.jp/LinkClick.aspx?fileticket=WMkupSZTnMI%3d&tabid=199&mid=759>

Newsweek は、世界に約 4,600 万人の読者を持つ米国の週刊誌で、世界の文化・政治・経済・社会情勢等、あらゆる分野の情報を世界に発信、展開しています。今回、特集企画「The Japanese Firms Accelerating Medical Innovation（医療革新を加速させる日本企業）」に、日本企業の一社として紹介されました。

なお、インタビューの全文は、ニュースサイト「The WORLDFOLIO」に掲載されていますので、あわせてお知らせいたします。

「The WORLDFOLIO」ウェブサイト（英文）

<https://www.theworldfolio.com/interviews/aska-we-create-new-value-as-leading-womens-healthcare-company/5872/>

※記事の掲載は The Worldfolio PTE. LTD.の許可を得ています。

The Worldfolio PTE. LTD.：

20 年以上にわたって世界中の読者に高品質のコンテンツを提供してきたメディアエージェンシーです。現在は、シンガポールを拠点に、製造、不動産、建設、ヘルスケア、デジタルトランスフォーメーションなど、幅広いトピックや最新ニュースを提供しています。

以上

＜お問い合わせ先＞

あすか製薬ホールディングス株式会社 グループ経営企画部 TEL：03-5484-8366

The World's Best Hospitals

INTERNATIONAL Newsweek®

Rx: AI

HOSPITAL
BOSSSES ARE
BETTING ON
BIG TECH

■ □ □



1 5 . 0 3 . 2 0 2 4

ISSN 2052-1081



ALBANIA €6.25	DENMARK DKR57	HONG KONG HK\$0	LITHUANIA €8.99	OMAN OR 3.250	SINGAPORE S\$11.95	UK £5.99
AUSTRALIA \$11.00	EGYPT E£ 65.00	HUNGARY HUF 5,990	LUXEMBOURG €7.90	POLAND PLN29.99	SLOVAKIA €6.50	US \$10.99
AUSTRIA €10.00	FINLAND €7.60	IRELAND €7.00	MALTA €7.00	PORTUGAL €7.00	SOUTH AFRICA R55.00	ZIMBABWE ZWD4.00
BAHRAIN BD4.25	FRANCE €7.50	ISRAEL NIS35	MONTENEGRO €8.30	QATAR QR65	SPAIN €7.00	
BELGIUM €7.00	GERMANY €7.50	ITALY €7.00	MOROCCO MDH70	MALAYSIA RM27.90	SWEDEN SKR119	
CHINA RMB80	GIBRALTAR £6.05	KUWAIT KD3.00	NEW ZEALAND \$14.00	ROMANIA LEI 42.00	SWITZERLAND	
CYPRUS €7.00	GREECE €7.50	LATVIA €6.50	NIGERIA \$3.40C	SAUDI ARABIA SR35.00	CHF10.60	
CZECH REP CZK180	HOLLAND €7.00	LEBANON LL10,000	NORWAY NKR119	S LEONE SLL30,000	UAE AED42	

ASKA Pharmaceutical: Revolutionizing Women's Healthcare

In its drive to become a women's healthcare pioneer, ASKA Pharmaceutical is committed to innovation and global expansion.



Head office in Tokyo

ASKA Pharmaceutical is today the leading force in Japan's obstetrics and gynecology sector, showcasing a relentless pursuit of excellence in women's healthcare that demonstrates its commitment beyond mere sales figures. "We aim to become a total healthcare company and a global entity, aligning with our corporate philosophy," says Sohta Yamaguchi, the company's president.

ASKA's strategic shift to a holdings model enables the company to offer comprehensive health



"We aim to become a total healthcare company and a global entity."

Sohta Yamaguchi,
President,
ASKA Pharmaceutical

services, from prevention to post-treatment, meeting the evolving needs of a proactive populace. With innovative products like RELUMINA (relugolix) for uterine fibroids and endometriosis, and essential products in the treatment of thyroid disease, ASKA Pharmaceutical stands out by providing effective solutions.


"We offer drugs that provide treatment options for women's health challenges at every stage of life," Mr. Yamaguchi explains. "We aim to not only provide

drugs and treatments but also medical equipment and related services, offering comprehensive health services for females."

And in a world where self-medication is on the rise, ASKA Pharmaceutical sees opportunities, not obstacles. "Over-

the-counter options are gaining popularity, and this has led to the growing health consciousness of the Japanese people and the revitalization of the healthcare market," he adds.

Looking forward, Mr. Yamaguchi en-



Three core areas with a focus on pharmaceuticals



Drugs for the treatment of thyroid disease when launched in 1922

visions a future where ASKA expands globally, enriching lives beyond Japan's borders. "By our 105th anniversary in 2025, I hope to report our successful achievements," he shares, hinting at forthcoming advancements in global expansion and new business ventures.

In a nutshell, ASKA Pharmaceutical isn't just about treating ailments; it's about empowering women, fostering health awareness, and pioneering innovations that transcend borders. With Mr. Yamaguchi at the helm, the company's journey towards global leadership in women's health seems not just promising but inevitable.

 **ASKA Pharmaceutical Co., Ltd.**
www.aska-pharma.co.jp